Sanofi S.A., FR0000120578

Sanofi expanded Regeneron alliance: Sanofi stock gains 1.34 percent

Published on 10/13/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi pays USD 1.00 billion upfront for four drugs. Sanofi stock is EUR 72.53 on October 13, 2026, plus 1.34 percent versus the Xetra close of EUR 71.57.

Key points in brief

Sanofi expanded its Regeneron alliance on October 1, 2026, adding four antibodies and potential payments of up to USD 8.00 billion.
Regeneron receives USD 1.00 billion upfront, while development and commercialization costs and future profits are split 50:50.
Sanofi stock was trading at EUR 72.53 at Lang & Schwarz on October 13, 2026, up 1.34 percent versus the Xetra close of EUR 71.57.
JPMorgan kept a Neutral rating and a EUR 95.00 price target on October 7, 2026.

Isometric 3D render of a translucent violet-blue cube containing a glowing molecular structure, a vaccine vial, a tablet blister pack, and a laboratory microscope — Sanofi FR0000120578 isometric 3D violet cube enclosing molecular structure, vaccine vial, blister pack, and microscope, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) was trading at EUR 72.53 at Lang & Schwarz on October 13, 2026 at 10:49 a.m. CEST, up 1.34 percent versus the Xetra close of EUR 71.57. Sanofi had expanded its Regeneron alliance on October 1, 2026, committing USD 1.00 billion upfront and potential milestone payments of up to USD 7.00 billion.

Three milestones shape the pipeline

On July 30, 2026, Sanofi reported second-quarter 2026 net sales of EUR 11.60 billion, up 17.80 percent year over year, according to ScanX.

On September 14, 2026, Sanofi agreed to transfer 20 mature medicines and three production sites to Cheplapharm in exchange for a 26.40 percent stake, as reported by Briefs.

On October 1, 2026, Sanofi said the expanded alliance would add four long-acting antibodies, with development and commercialization costs and future profits split 50:50.

What does the alliance change?

The deal adds a clinical-stage IL-13 antibody and three other programs targeting IL-4, IL-13 and the IL-4 receptor alpha. The lead asset, REGN20423, is in a phase 1 study for atopic dermatitis, while the other three programs are expected to enter clinical studies in 2027.

The commercial logic is important because the alliance extends Sanofi's immunology platform beyond the existing Dupixent franchise. Regeneron will lead research and development, while Sanofi will lead global commercial efforts. The 50:50 economics limit Sanofi's development burden, but the programs remain early-stage and carry clinical and regulatory risk.

Analysts and upcoming dates

JPMorgan kept Sanofi at Neutral with a EUR 95.00 price target in a note dated October 7, 2026, according to Finanzen. The target stands 30.98 percent above the Lang & Schwarz price, keeping the market discussion centered on pipeline execution rather than the alliance headline alone.

Sanofi's third-quarter 2026 results are scheduled for October 30, 2026, and the company has listed the Jefferies Global Healthcare Conference for November 17, 2026, on its investor-relations calendar at Sanofi.

Sanofi stock remains below its yearly high

The stock's current EUR 72.53 Lang & Schwarz price sits within the EUR 69.75 to EUR 91.15 52-week range as of October 13, 2026. Sanofi's market capitalization was EUR 87.1 billion on the same date, while the stock was 1.34 percent above the Xetra close of October 12, 2026 at EUR 71.57.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.